We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

174 hedge funds and large institutions have $365M invested in Verve Therapeutics in 2024 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 62 increasing their positions, 46 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 24

35% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 46

5% more funds holding

Funds holding: 166 → 174 (+8)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less capital invested

Capital invested by funds: $372M → $365M (-$7.11M)

1.7% less ownership

Funds ownership: 90.65% → 88.95% (-1.7%)

65% less call options, than puts

Call options by funds: $414K | Put options by funds: $1.19M

Holders
174
Holders Change
+8
Holders Change %
+4.82%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
33
Increased
62
Reduced
46
Closed
24
Calls
$414K
Puts
$1.19M
Net Calls
-$771K
Net Calls Change
-$343K

Top Buyers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
+$14M
2
Millennium Management
Millennium Management
New York
+$6.34M
3
CC
Casdin Capital
New York
+$5.44M
4
State Street
State Street
Massachusetts
+$5.25M
5
N
Nuveen
North Carolina
+$5M

Top Sellers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
-$17.1M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$12.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$7.31M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$6.64M
5
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$5.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$2.79M +$29.3K +5,044 +0.9%
PAI
27
Palo Alto Investors
California
$2.79M – – –
Renaissance Technologies
28
Renaissance Technologies
New York
$2.78M +$582K +100,286 +21%
Charles Schwab
29
Charles Schwab
California
$2.77M +$732K +126,110 +28%
TI
30
Trexquant Investment
Connecticut
$2.69M +$186K +32,109 +6%
VPC
31
Vestal Point Capital
New York
$2.54M +$145K +25,000 +5%
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$2.09M -$26.8K -4,619 -1%
Two Sigma Investments
33
Two Sigma Investments
New York
$2.08M -$1.03M -177,199 -29%
CAM
34
Cormorant Asset Management
Massachusetts
$1.69M – – –
Wellington Management Group
35
Wellington Management Group
Massachusetts
$1.68M -$141K -24,271 -7%
Los Angeles Capital Management
36
Los Angeles Capital Management
California
$1.27M +$116K +19,925 +8%
Ameriprise
37
Ameriprise
Minnesota
$1.09M +$271K +46,638 +26%
AG
38
Algert Global
California
$1.08M +$504K +86,720 +63%
Barclays
39
Barclays
United Kingdom
$1.08M +$755K +129,944 +140%
Jane Street
40
Jane Street
New York
$1.05M -$214K -36,899 -15%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$1.04M -$346K -59,633 -22%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$1.02M -$89.4K -15,392 -7%
Acadian Asset Management
43
Acadian Asset Management
Massachusetts
$932K +$1.12M +192,766 New
Two Sigma Advisers
44
Two Sigma Advisers
New York
$893K -$314K -54,100 -23%
PP
45
PDT Partners
New York
$880K -$883K -152,061 -46%
IC
46
Ikarian Capital
Texas
$823K +$987K +170,000 New
UBS Group
47
UBS Group
Switzerland
$794K +$334K +57,425 +54%
ACP
48
Acuta Capital Partners
California
$707K +$849K +146,100 New
Stifel Financial
49
Stifel Financial
Missouri
$636K +$97.8K +16,842 +15%
HF
50
HRT Financial
New York
$613K +$737K +126,859 New
1
2
3 4 5

VERV Hedge Fund Activity: Q3 2024 in Review

174 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2024, worth a combined $365M — down 1.9% from $372M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new VERV positions and 24 closed out — a net gain of 9 holders — while 62 added to existing stakes and 46 trimmed.

The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $14M. The largest seller was ARK Investment Management, exiting entirely with an estimated $17.1M sold.

  • 174 institutional investors held Verve Therapeutics (VERV) as of Q3 2024, up from 166 in Q2 2024.
  • Funds reported $365M of Verve Therapeutics stock for Q3 2024, down 1.9% quarter-over-quarter.
  • 33 funds opened new Verve Therapeutics positions in Q3 2024 and 24 closed out, a net change of +9 holders.
  • The largest Verve Therapeutics buyer in Q3 2024 was Schonfeld Strategic Advisors, an estimated $14M added.
  • The largest Verve Therapeutics seller in Q3 2024 was ARK Investment Management, an estimated $17.1M sold.

Based on aggregated 13F filings for Q3 2024.